Analyst Reco. Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
40.56 ^USD	-0.12%		-4.70%	-32.24%

May. 24	Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases	MT
May. 24	Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Adjusts Price Target on Apellis Pharmaceuticals to $48 From $57, Maintains Equal-Weight Rating	May. 23	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing	May. 09	MT
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating	May. 08	MT
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating	May. 08	MT
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating	Apr. 29	MT
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating	Apr. 17	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	Apr. 09	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	Mar. 21	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	Mar. 20	MT
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating	Mar. 06	MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating	Mar. 04	MT
Wedbush Raises Apellis Pharmaceuticals' PT to $67 From $60, Keeps Neutral Rating; Says Awaiting Further Clarity on Potential EU Regulatory Path for Syfovre	Feb. 28	MT
Mizuho Raises PT on Apellis Pharmaceuticals to $60 From $49 Ahead of Q4 2023 Earnings Announcement, Keeps Neutral Rating	Feb. 15	MT
UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating	Feb. 13	MT
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Jefferies Upgrades Apellis Pharmaceuticals to Buy From Hold, Adjusts Price Target to $80 From $68	Feb. 05	MT
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $79 From $75, Maintains Outperform Rating	Jan. 30	MT
Needham Adjusts Price Target on Apellis Pharmaceuticals to $75 From $70, Maintains Buy Rating	Jan. 24	MT
Wells Fargo Raises Apellis Pharmaceuticals' Price Target to $62 From $54, Maintains Equalweight Rating	Jan. 17	MT
Baird Adjusts Apellis Pharmaceuticals' Price Target to $81 From $71, Maintains Outperform Rating	Jan. 17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Analyst Reco.

Filters